{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:56:44Z","timestamp":1774342604737,"version":"3.50.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2026.1811781","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:24:32Z","timestamp":1774329872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Epcoritamab plus R\u00b2 in follicular lymphoma: practice-changing efficacy meets unresolved toxicity trade-offs"],"prefix":"10.3389","volume":"16","author":[{"given":"Qinghua","family":"Ke","sequence":"first","affiliation":[{"name":"Department of Chemoradiotherapy, The First People\u2019s Hospital of Jingzhou","place":["Jingzhou, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Chemoradiotherapy, The First People\u2019s Hospital of Jingzhou","place":["Jingzhou, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of Malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/2326-6066.CIR-23-0072","article-title":"T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing","volume":"12","author":"Besla","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01778-7","article-title":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","volume":"407","author":"Sehn","year":"2026","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018546","article-title":"Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed\/refractory follicular lymphoma","author":"Iacoboni","year":"2026","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: A national lymphoCare study and center for international blood and marrow transplant research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70018","article-title":"Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper","volume":"207","author":"Chaganti","year":"2025","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811781\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:24:33Z","timestamp":1774329873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811781\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":11,"alternative-id":["10.3389\/fonc.2026.1811781"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1811781","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"1811781"}}